Solid Tumor Targeting CAR-T Development Service with Dominant-Negative TGF-βRII

Creative Biolabs offers a specialized Solid Tumor Targeting CAR-T Development Service featuring Dominant-Negative TGF-βRII armoring to counteract cytokine-mediated immunosuppression in solid tumors. Our platform enables the engineering of CAR-T cells intrinsically resistant to TGF-β–driven inhibition, resulting in enhanced persistence, metabolic fitness, and sustained effector function within hostile tumor microenvironments such as glioblastoma and prostate cancer. By integrating advanced receptor engineering with robust validation workflows, we deliver high-potency CAR-T candidates optimized for durable anti-tumor activity.

Introduction

TGF-β signaling is a major barrier to effective CAR-T therapy in solid tumors, driving T-cell dysfunction and immune escape. Dominant-negative TGF-βRII engineering has emerged as a validated strategy to block suppressive signaling while preserving CAR-T activation and persistence. Published studies support its role in improving antitumor efficacy across multiple solid tumor models.

Fig.1 The structures of tumor-targeting CARs with different designs.¹

Service

Creative Biolabs provides an integrated development solution to engineer CAR-T cells capable of maintaining effector function within TGF-β rich solid tumor microenvironments. Our service focuses on rational CAR construct design, dominant-negative TGF-βRII incorporation, and functional validation to support preclinical research and translational programs.

Our team provides end-to-end solutions, including CAR design consultation, vector construction, T-cell transduction and expansion, functional validation, and mechanistic characterization. We guide clients through the selection of optimal tumor-associated antigens, design of co-stimulatory domains, and integration of dnTGF-βRII to maximize both safety and efficacy. This service ensures that CAR-T cells produced are rigorously tested for cytotoxic activity, cytokine secretion, and resistance to suppressive factors, providing reliable preclinical data for translational research.

Discover How We Can Help - Request a Consultation.

Key Technology Platforms

For robust development and analysis of dnTGF-βRII enhanced CAR-T cells, Creative Biolabs leverages multiple advanced platforms and experimental strategies without relying on proprietary methods. Key technology platforms include:

Additional complementary experiments include cell phenotyping, proliferation tracking, and mechanistic assays to assess CAR-T durability and anti-suppressive capacity. By integrating these platforms, Creative Biolabs provides a comprehensive framework for designing, validating, and optimizing dnTGF-βRII enhanced CAR-T cells, ensuring clients have actionable insights for translational and preclinical development.

Process flow

Final Deliverables

• Fully characterized dnTGF-βRII–armored CAR-T cell lines
• Functional evaluation reports, including cytotoxicity and suppression-resistance data
• Experimental protocols and summarized data packages for downstream development

Key Advantages

• Flexible and Scalable Solutions: Services are compatible with primary T cells, donor-specified populations, and customizable CAR designs. The platform supports rapid iteration and scalability, facilitating seamless progression from research to preclinical applications.
• Evidence-Based Approach: Leveraging published data and internal validation studies, our service ensures CAR-T constructs demonstrate measurable improvements in anti-tumor efficacy, functional durability, and TGF-β resistance. Clients benefit from actionable insights supported by experimental evidence.
• Streamlined Project Support: From vector construction to mechanistic analyses, we provide clear timelines, detailed reports, and standardized protocols, reducing experimental risks and accelerating project timelines.

FAQs

Partner with Us

Creative Biolabs delivers advanced Solid Tumor Targeting CAR-T Development Services with Dominant-Negative TGF-βRII, empowering researchers to overcome tumor-induced immunosuppression and advance next-generation CAR-T therapies. We combine immunoengineering expertise with robust validation workflows to support realistic and reproducible CAR-T development for solid tumors. Our service emphasizes biological relevance, functional rigor, and translational readiness. Contact Our Team for More Information and to Discuss Your Project.

Reference

1. Tian, Yonggui et al. "Gene modification strategies for next-generation CAR T cells against solid cancers." Journal of hematology & oncology vol. 13,1 54. 18 May. 2020. Distributed under Open Access License CC BY 4.0, without modification. https://doi.org/10.1186/s13045-020-00890-6